Cite
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
MLA
Zimmermann, Heiner, et al. “Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.” Transplantation, vol. 102, no. 11, Nov. 2018, pp. 1914–23. EBSCOhost, https://doi.org/10.1097/TP.0000000000002269.
APA
Zimmermann, H., Babel, N., Dierickx, D., Morschhauser, F., Mollee, P., Zaucha, J. M., Dreyling, M. H., Dührsen, U., Reinke, P., Verhoef, G., Subklewe, M., Hüttmann, A., Tousseyn, T., Bachy, E., Hauser, I. A., Tarella, C., Van Den Neste, E., Gheysens, O., Anagnostopoulos, I., … Trappe, R. U. (2018). Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. Transplantation, 102(11), 1914–1923. https://doi.org/10.1097/TP.0000000000002269
Chicago
Zimmermann, Heiner, Nina Babel, Daan Dierickx, Franck Morschhauser, Peter Mollee, Jan M Zaucha, Martin H Dreyling, et al. 2018. “Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.” Transplantation 102 (11): 1914–23. doi:10.1097/TP.0000000000002269.